{"transactions":[{"id":1627945,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":1,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-02-21T16:20:10.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":155035,"price":10,"value":1550350.0,"ownership":{"direct":false,"nature":"Held by Lumira Ventures IV (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is filed jointly by Lumira Ventures III, L.P. (\"Lumira III\"), Lumira Ventures III (International), L.P. (\"Lumira III Int'l\"), Lumira Ventures IV, L.P. (\"Lumira IV\"), Lumira Ventures IV (International), L.P. (\"Lumira IV Int'l\"), Merck Lumira Biosciences Fund, L.P. (\"Merck-Lumira\"), Merck Lumira Biosciences Fund (Quebec), L.P. (\"Merck-Lumira B\" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the \"Lumira Entities\"), Lumira Capital Investment Management Inc. (\"Lumira Mgmt\"), Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc. and Lumira GP Holdings Co. (collectively, the \"Reporting Person\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Gerald Brunk, a director of the Issuer, is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt and reports his beneficial ownership of these securities on a separate Form 4. Each of Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":238851,"source":{"system":"sec-edgar","filing":"0000905148-24-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1702636/000090514824000773/form4.xml","form_type":"4"}},{"id":1627944,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":1,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-02-21T16:20:10.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":644965,"price":10,"value":6449650.0,"ownership":{"direct":false,"nature":"Held by Lumira Ventures IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is filed jointly by Lumira Ventures III, L.P. (\"Lumira III\"), Lumira Ventures III (International), L.P. (\"Lumira III Int'l\"), Lumira Ventures IV, L.P. (\"Lumira IV\"), Lumira Ventures IV (International), L.P. (\"Lumira IV Int'l\"), Merck Lumira Biosciences Fund, L.P. (\"Merck-Lumira\"), Merck Lumira Biosciences Fund (Quebec), L.P. (\"Merck-Lumira B\" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the \"Lumira Entities\"), Lumira Capital Investment Management Inc. (\"Lumira Mgmt\"), Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc. and Lumira GP Holdings Co. (collectively, the \"Reporting Person\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Gerald Brunk, a director of the Issuer, is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt and reports his beneficial ownership of these securities on a separate Form 4. Each of Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":993651,"source":{"system":"sec-edgar","filing":"0000905148-24-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702636/000090514824000773/form4.xml","form_type":"4"}},{"id":2056296,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":12895,"price":2.6346,"value":33973.167,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":150275,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2056295,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":139450,"price":2.6346,"value":367394.97,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1625133,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2056294,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":12284,"price":2.6621,"value":32701.2364,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":163170,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2056293,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":132845,"price":2.6621,"value":353646.6745,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1764583,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2994236,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":false,"shares":5952,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":5952},"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":2994235,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":false,"shares":64362,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":64362},"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":2994234,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":true,"shares":5952,"price":4,"value":23808.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":175454,"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":2994233,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":true,"shares":64362,"price":4,"value":257448.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1897428,"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":3312361,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":5952,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5952,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":5952},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312360,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":64362,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":64362,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":64362},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312359,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":8928,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":8928,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":8928},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312358,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":96542,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":96542,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":96542},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312357,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":11903,"price":3.2,"value":38089.6,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":169502,"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312356,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":128722,"price":3.2,"value":411910.4,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1833066,"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3313106,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":5952,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5952,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":5952},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313105,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":64362,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":64362,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":64362},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313104,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":8928,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":8928,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":8928},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313103,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":96542,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":96542,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":96542},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313102,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":11903,"price":3.2,"value":38089.6,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":169502,"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313101,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":128722,"price":3.2,"value":411910.4,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1833066,"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3452999,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-07-30T23:22:43.000Z","date":"2019-07-26","kind":"grant","acquired":true,"shares":8600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents additional common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the \"Issuer\") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. (\"Edesa\"), and the shareholders of Edesa.  The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders."},{"field":"shares","element":"transactionShares","label":"F2","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":157599,"source":{"system":"sec-edgar","filing":"0001104659-19-042699","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000110465919042699/a4.xml","form_type":"4"}},{"id":3452998,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-07-30T23:22:43.000Z","date":"2019-07-26","kind":"grant","acquired":true,"shares":93006,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents additional common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the \"Issuer\") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. (\"Edesa\"), and the shareholders of Edesa.  The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders."},{"field":"shares","element":"transactionShares","label":"F2","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1704344,"source":{"system":"sec-edgar","filing":"0001104659-19-042699","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000110465919042699/a4.xml","form_type":"4"}},{"id":3493755,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-11T21:52:35.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":148999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the \"Issuer\") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. and the shareholders of Edesa Biotech Inc."},{"field":"shares","element":"transactionShares","label":"F3","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. [\"LCII LP\"], (ii) Lumira Capital II (International), L.P. [\"LCII INT LP\"], (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co. and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc. Lumira GP Holdings Co. and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":148999,"source":{"system":"sec-edgar","filing":"0001144204-19-030609","document":"tv523428_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000114420419030609/tv523428_4.xml","form_type":"4"}},{"id":3493754,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-11T21:52:35.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":1611338,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the \"Issuer\") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. and the shareholders of Edesa Biotech Inc."},{"field":"shares","element":"transactionShares","label":"F3","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. [\"LCII LP\"], (ii) Lumira Capital II (International), L.P. [\"LCII INT LP\"], (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co. and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc. Lumira GP Holdings Co. and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1611338,"source":{"system":"sec-edgar","filing":"0001144204-19-030609","document":"tv523428_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000114420419030609/tv523428_4.xml","form_type":"4"}}]}